KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Cash & Equivalents (2016 - 2025)

Charles River Laboratories International has reported Cash & Equivalents over the past 17 years, most recently at $213.8 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $213.8 million for Q4 2025, up 9.85% from a year ago — trailing twelve months through Dec 2025 was $213.8 million (up 9.85% YoY), and the annual figure for FY2025 was $213.8 million, up 9.85%.
  • Cash & Equivalents for Q4 2025 was $213.8 million at Charles River Laboratories International, up from $207.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CRL hit a ceiling of $465.4 million in Q1 2021 and a floor of $157.2 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $211.4 million (2021), compared with a mean of $229.6 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 48.03% in 2022 and later soared 62.23% in 2024.
  • Charles River Laboratories International's Cash & Equivalents stood at $241.2 million in 2021, then fell by 3.03% to $233.9 million in 2022, then increased by 18.32% to $276.8 million in 2023, then dropped by 29.69% to $194.6 million in 2024, then increased by 9.85% to $213.8 million in 2025.
  • The last three reported values for Cash & Equivalents were $213.8 million (Q4 2025), $207.1 million (Q3 2025), and $182.8 million (Q2 2025) per Business Quant data.